Butenafine Hydrochloride
Based on 1 publication(s) in Google Scholar
Butenafine Hydrochloride (KP363 Hydrochloride) is a synthetic benzylamine antifungal, works by inhibiting the synthesis of sterols by inhibiting squalene epoxidase.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.95%
- CAS. Nr.: 101827-46-7
- Formel: C23H28ClN
- Molecular Weight:353.93
-
Speicherung:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-17395
Terbinafine hydrochlorideAntimicrobial Agent -
HY-10882
ClotrimazoleAutophagy Inhibitor -
HY-17396R
Butenafine Hydrochloride (Standard)Antibiotic -
HY-13832
AtovaquoneAntimalarial Agent -
HY-14272
RavuconazoleAntifungle Agent -
HY-B0370
TolnaftateFungal Inhibitor -
HY-14273
IsavuconazoleTriazole Antifungal -
HY-14273R
Isavuconazole (Standard)Triazole Antifungal -
HY-B0370R
Tolnaftate (Standard)Fungal Inhibitor -
HY-76200
VoriconazoleAntifungal Agent -
HY-17514
ItraconazoleAntifungal Agent -
HY-B0453
Econazole nitrateAntifungal Agent
Publications Citing Use of MedChemExpress (MCE) Butenafine Hydrochloride
MoreAlle Antibiotic Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
Antifungal; squalene epoxidase
In Vitro
Butenafine Hydrochloride, a benzylamine derivative, is an antifungal which is used to control dermal fungal infections such as athletes foot and ring worm. Butenafine Hydrochloride is squalene epoxidase inhibitor, inhibits the synthesis of ergosterol needed in fungal cell membranes. The drug has excellent penetration into the epidermis and a prolonged retention time following topical application, conferring residual therapeutic activity after treatment cessation. Butenafine possess anti-inflammatory activity too. Butenafine hydrochloride 1% cream is safe and effective for tinea corporis cruris and tinea manuum pedis.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 101827-46-7
-
Appearance Solid
-
Molecular Weight 353.93
-
Formel C23H28ClN
-
Color White to off-white
-
SMILES
CN(CC1=CC=C(C(C)(C)C)C=C1)CC2=C3C=CC=CC3=CC=C2.[H]Cl
-
Synonyms
KP363 Hydrochloride
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Death Dis
Targeting epigenetic modulation of cholesterol synthesis as a therapeutic strategy for head and neck squamous cell carcinoma. [Abstract]2021 May 13;12(5):482. PMID: 33986254
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 25 mg/mL (70.64 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 1 mg/mL (2.83 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.06 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.06 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Singal A. Butenafine and superficial mycoses: current status. Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):999-1005. [Content Brief]
[2]. Kokjohn K, Bradley M, Griffiths B, Ghannoum M. Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria. Int J Dermatol. 2003 Sep;42 Suppl 1:11-7. [Content Brief]
[3]. Syed TA, Maibach HI. Butenafine hydrochloride: for the treatment of interdigital tinea pedis. Expert Opin Pharmacother. 2000 Mar;1(3):467-73. [Content Brief]
[4]. McNeely W, Spencer CM. Butenafine. Drugs. 1998 Mar;55(3):405-12; discussion 413. [Content Brief]
[5]. Butenafine
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.8254 mL | 14.1271 mL | 28.2542 mL | 70.6354 mL |
| DMSO | 5 mM | 0.5651 mL | 2.8254 mL | 5.6508 mL | 14.1271 mL |
| 10 mM | 0.2825 mL | 1.4127 mL | 2.8254 mL | 7.0635 mL | |
| 15 mM | 0.1884 mL | 0.9418 mL | 1.8836 mL | 4.7090 mL | |
| 20 mM | 0.1413 mL | 0.7064 mL | 1.4127 mL | 3.5318 mL | |
| 25 mM | 0.1130 mL | 0.5651 mL | 1.1302 mL | 2.8254 mL | |
| 30 mM | 0.0942 mL | 0.4709 mL | 0.9418 mL | 2.3545 mL | |
| 40 mM | 0.0706 mL | 0.3532 mL | 0.7064 mL | 1.7659 mL | |
| 50 mM | 0.0565 mL | 0.2825 mL | 0.5651 mL | 1.4127 mL | |
| 60 mM | 0.0471 mL | 0.2355 mL | 0.4709 mL | 1.1773 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Butenafine Hydrochloride Related Classifications
HY-17396 Related Classifications
Powered by Bioz